CytomX Therapeutics, Inc. — Director's Dealing 2018

Dec 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CytomX Therapeutics, Inc. (CTMX)
CIK: 0001501989
Period of Report: 2018-12-12

Reporting Person: RAY DEBANJAN (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-12	Common Stock	M	3000	$1.4489	Acquired	8928	Direct
2018-12-12	Common Stock	S	3000	$15.00	Disposed	5928	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-12	Stock Option (Right to Buy)	$1.4489	M	3000	Disposed	2024-02-27	Common Stock (3000)	Direct

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: 100% of the shares subject to the option are fully vested and exercisable.